USFDA approves Phoenix IND 73,624 application to conduct a Phase I Trial with PBI-05204, a patented supercritical extract of Nerium oleander, in patients with advanced cancer.USFDA approves Phoenix IND 73,624 application to conduct a Phase I Trial with PBI-05204, a patented supercritical extract of Nerium oleander, in patients with advanced cancer.
Follow us in:
Follow us on:
Contact Us
Copyright © Salud Integral, Tegucigalpa, Honduras | Powered by hmd.consulting | Term of use | Privacy policy